These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 27070359)
61. Distinct clinical characteristics of atypical optic neuritis with seronegative aquaporin-4 antibody among Chinese patients. Zhou H; Xu Q; Zhao S; Wang W; Wang J; Chen Z; Lin D; Li X; Peng C; Ai N; Wei S Br J Ophthalmol; 2017 Dec; 101(12):1720-1724. PubMed ID: 28404667 [TBL] [Abstract][Full Text] [Related]
62. Complexity and heterogeneity in demyelinating disease. Compston A Brain; 2007 May; 130(Pt 5):1178-80. PubMed ID: 17472981 [No Abstract] [Full Text] [Related]
63. Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid. Long Y; Chen M; Zhang B; Gao C; Zheng Y; Xie L; Gao Q; Yin J J Neuroimmunol; 2014 Apr; 269(1-2):62-7. PubMed ID: 24582827 [TBL] [Abstract][Full Text] [Related]
64. Neuromyelitis optica spectrum disorder (NMOSD): A new concept. de Sèze J; Kremer L; Collongues N Rev Neurol (Paris); 2016; 172(4-5):256-62. PubMed ID: 27157418 [TBL] [Abstract][Full Text] [Related]
65. [AQP4 immunohistochemistry in neuromyelitis optica and multiple sclerosis: a neuropathological review]. Yoshida M Brain Nerve; 2010 Sep; 62(9):961-74. PubMed ID: 20844307 [TBL] [Abstract][Full Text] [Related]
66. A previously misdiagnosed cohort of aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder with disease duration of >10 years in multi-ethnic Penang, Malaysia: Clinical features and disease course. Hor JY; Lim TT; Chow HB; Tan K; Cheah CF; Ching YM; Arip M; Easaw PE; Eow GB Mult Scler Relat Disord; 2016 Jan; 5():89-90. PubMed ID: 26856950 [No Abstract] [Full Text] [Related]
67. [Prospects for Treatment of Neuromyelitis Optica Spectrum Disorder]. Nakashima I Brain Nerve; 2020 Jan; 72(1):61-68. PubMed ID: 31907333 [TBL] [Abstract][Full Text] [Related]
68. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Misu T; Fujihara K; Kakita A; Konno H; Nakamura M; Watanabe S; Takahashi T; Nakashima I; Takahashi H; Itoyama Y Brain; 2007 May; 130(Pt 5):1224-34. PubMed ID: 17405762 [TBL] [Abstract][Full Text] [Related]
69. Neuromyelitis optica spectrum disorder and multiple sclerosis: Differentiation by a multimodal approach. Ota M; Sato N; Okamoto T; Noda T; Araki M; Yamamura T; Kunugi H Mult Scler Relat Disord; 2015 Nov; 4(6):515-20. PubMed ID: 26590657 [TBL] [Abstract][Full Text] [Related]
70. Large-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder Based on New Diagnostic Criteria. Kim Y; Kim G; Kong BS; Lee JE; Oh YM; Hyun JW; Kim SH; Joung A; Kim BJ; Choi K; Kim HJ J Clin Neurol; 2017 Apr; 13(2):175-180. PubMed ID: 28271642 [TBL] [Abstract][Full Text] [Related]
71. Incidence and Prevalence of Neuromyelitis Optica Spectrum Disorders in the Background of International Consensus Diagnostic Criteria - A Systematic Review. Pandit L; D'Cunha A; Malapur PU Neurol India; 2022; 70(5):1771-1779. PubMed ID: 36352564 [TBL] [Abstract][Full Text] [Related]